Skip to main content

Advertisement

Table 1 Characteristics of the three PDXs used

From: Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts

PDX ID DIAGNOSIS TP53 status IHC
    PTEN NF1 p-ERK
MNHOC124 Serous/endometroid mut - ++ +++
MNHOC218 Endometroid mut - + ++
MNHOC239 Serous mut - ++ ++
  1. IHC Immunoistochemistry. Protein expression was cytoplasmic with no nuclear or membrane-associated staining. The intensity of the staining has been ranked according to the following scale: - negative; +/- slight/doubtful; + slight; ++ moderate; +++ marked
  2. Mut: mutated